News

Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-label Public reimbursement for...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results on Thursday, August 11, 2022. The Company will hold a conference call...

Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label Public reimbursement for Vascepa is now...

New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will reimburse Vascepa for the reduction of cardiovascular risk in...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Bill Wells, Executive Chair of the...

Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular disease Private drug plan reimbursement for Vascepa is...

Q1 2022 revenue of $14.6 million, Adjusted EBITDA of $6.3 million and cash from operations of $5.8 million. Vascepa® prescriptions grew 12% sequentially and 111% year-over-year in Q1 2022 amid...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2022 financial results on Thursday, May 5, 2022. The Company will hold a conference call...

Enters into Letter of Intent (LOI) that paves the way for product listing agreements for Vascepa with all of Canada's provinces and territories. Public market access is expected to be a...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...

Q4 2021 revenue of $15.7 million, Adjusted EBITDA of $6.2 million and cash from operations of $4.0 million 2021 revenue of $60.0 million, Adjusted EBITDA of $26.3 million and cash from operations...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 & Fiscal 2021 financial results on Thursday, March 17, 2022. The Company will hold a conference...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that in connection with its previously...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...

Q3 2021 revenue of $15.1 million and Adjusted EBITDA of $6.9 million, up 15% and 53%, respectively, from Q3 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2021 financial results on Thursday, November 4, 2021. The Company will hold a conference call that...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in two...

Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary...

Q2 2021 revenue of $14.9 million and Adjusted EBITDA of $6.6 million, up 19% and 36%, respectively, from Q2 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2021 financial results on Thursday, August 5, 2021. The Company will hold a conference call that...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...

Q1 2021 revenue of $14.3 million, Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million, up $0.4 million, $0.6 million and $1.8 million, respectively, from Q1 2020 Vascepa...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021. The Company will hold a conference call that same...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...

HLS Therapeutics Inc. regrets the adoption of a new regulation, published yesterday in the Gazette officielle du Québec, which limits access to a support program for new patients suffering from...

Dorval, le 1er avril 2021. — HLS Therapeutics Inc. déplore l’adoption d’un nouveau règlement, publié hier dans la Gazette officielle du Québec, qui aura des conséquences sur l’accès...

CCS dyslipidemia management guidelines published in the Canadian Journal of Cardiology (CJC) on March 26, 2021 Strong recommendation for the use of icosapent ethyl for Primary Prevention (diabetes...

Fourth quarter revenue of $16.5 million, Adjusted EBITDA of $8.7 million and cash from operations of $5.8 million Produced strong Vascepa® prescription growth amid COVID-19 challenges: more than...

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%,...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and fiscal 2020 financial results by press release at 6:30 a.m. EST on Thursday, March 18, 2021....

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will participate in...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will be participating...

Private payer health plan coverage in Canada for Vascepa is expected to reach more than 80% by the end of February 2021, up from 50% in November 2020 Coverage effective for statin-treated patients...

Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology1 Chinese Society of Cardiology updated Guidelines now include...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it intends to redeem the...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that John L. Welborn, Jr.,...

Health Canada approves MyCare Psychiatry Lab Assays for use in diagnostic lab settings to measure blood levels in patients prescribed six of the most common antipsychotic drugs MyCare Insite...

Results presented in Late Breaker session at National Lipid Association Scientific Sessions 2020 Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in connection with its...

first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia once-monthly dosing may help improve treatment compliance PERSERIS is a first-line treatment option for...

Results from Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association's Virtual Scientific Sessions 2020 VASCEPA®, compared with placebo, significantly...